Current News

UC Davis Veterinary Ophthalmologist Has Success with Alternative Surgery to Treat Cornea Disease, Hopes to Discover Gene Causing the Disease

What's New Image

Cyrus benefitted from two separate clinical trials involving cornea disease, helping him to see better.

Life wasn’t looking too bright last year for Cyrus, a 10-year-old German shorthaired pointer (GSP). Not only had he lost his home, he was also losing his sight. Living in a shelter, Cyrus was suffering from corneal endothelial dystrophy (CED), a disease in the eyes that causes premature degeneration of endothelial cells, which are critical to pumping fluid out of the cornea and maintaining transparency.

CED is a devastating disease in dogs that can result in blindness and severe ocular pain from secondary complications. The endothelial cells comprise the most inner aspect of the cornea and are responsible for maintaining a proper fluid balance. This function is critical to ensuring that the cornea remains transparent for vision. In many animals, including dogs, corneal endothelial cells have a very limited capacity to regenerate following injury. In canine patients with CED, the endothelial cells degenerate until the cells still remaining can no longer function properly. This results in swelling of the cornea which results in decreased vision, as well as formation of small fluid-filled blisters (bullae) on the cornea which can rupture and cause ocular discomfort.

There are palliative treatments such as hypertonic saline to decrease corneal bullae formation, but the only definitive treatment for this condition is a corneal transplant (penetrating keratoplasty). Unfortunately, corneal transplants are rarely performed in canine patients with CED due to the expense of the surgery and follow-up care, relatively high risk of complications, and lack of appropriate donor tissue.

CED is seen more commonly in GSPs in comparison to many other breeds. This observation suggests that this disease may have a genetic component. Luckily for Cyrus and other GSPs, the UC Davis Veterinary Medical Teaching Hospital is conducting a clinical trial to identify the region of the dog genome associated with CED in GSPs.

NorCal GSP Rescue in Menlo Park, California found Cyrus, pulled him from the shelter, brought him to UC Davis and enrolled him in the trial. NorCal GSP Rescue knew from prior visits to UC Davis the capableness of the hospital’s Ophthalmology Service. Researchers in the on-going clinical trial, led by Dr. Sara Thomasy, hope that once the CED-causing gene is identified and isolated, they will be able to create a genetic test to allow breeders to avoid producing dogs with CED.

While Cyrus was helping UC Davis learn more about CED, Dr. Thomasy was considering whether a prior clinical trial on an alternative surgery to treat CED might hold promise for Cyrus.

“Based on the results of Cyrus’ CED study, I was worried that he may not be a good candidate for the surgery,” said Dr. Thomasy. “His corneas were the thickest of any dogs on which this surgery had been performed.”

The prior surgery trial—conducted in conjunction with Animal Eye Center in Rocklin, California—was performed to discover the efficacy of an alternative to corneal transplant surgery (penetrating keratoplasty). The alternative surgery involves performing a superficial keratectomy (removing part of the anterior or front aspect of the cornea) then placing a very thin conjunctival advancement flap over the removed portion. Known as a SKCAHF (superficial keratectomy and conjunctival advancement hood flap) surgery, the procedure thins the cornea in the region where the surgery is performed, and interestingly enough (for reasons unknown to researchers at this point), also in the central region that is left untouched. The alternative surgery trial showed promising results in nine enrolled patients, one of which was a GSP.

Based on the success of the SKCAHF surgery trial, Dr. Thomasy had reason to believe it would work on Cyrus, even though his corneas were so thick. Cyrus underwent a successful SKCAHF surgery in March 2014. At three months following surgery, he had markedly improved corneal clarity and vision.

“We did know that the SKCAHF surgery trial had been very successful in other dogs, including another GSP, but that dog had more moderate disease,” said Dr. Thomasy. “Cyrus’ results are exciting because we now know this surgery can help dogs with severe disease, too.”

Cyrus’ corneas are now less thick and clearer. Most importantly, his foster family reports that his vision has dramatically improved. (UPDATE: Cyrus has been adopted.)

UC Davis is still actively recruiting new candidates to find the genetic cause for CED in several dog breeds. If you have a GSP, German wirehaired pointer, or a Boston terrier with CED, please contact Dr. Thomasy via email (smthomasy@ucdavis.edu) or phone (530-752-1770).

#  #  #

This success story was made possible, in part, by generous donations to the School of Veterinary Medicine’s “Compassionate Care Funds,” which are used to help families defray costs involved with treating their sick or injured animals, and to treat shelter, stray and wild animals brought to the UC Davis veterinary hospital. To make a tax-deductible contribution to this fund, please visit http://bit.ly/14bRVXZ.

See more photos of Cyrus here: https://www.facebook.com/media/set/?set=a.10152726883989031.1073741863.164666034030&type=1
 



About the Veterinary Medical Teaching Hospital
The William R. Pritchard Veterinary Medical Teaching Hospital at the University of California, Davis—a unit of the School of Veterinary Medicine—provides state-of-the-art clinical care while serving as the primary clinical teaching experience for DVM students and post graduate veterinarian residents. The VMTH treats more than 47,000 animals a year, ranging from cats and dogs to horses, cows and exotic species. To learn more about the VMTH, please go to www.vetmed.ucdavis.edu/vmth. Timely news updates can be received on its Facebook (www.facebook.com/ucdavisvetmed) and Twitter (www.twitter.com/ucdavisvetmed) pages.

Rob Warren
VMTH Communications & Marketing Officer
rjwarren@ucdavis.edu
530-752-2363